Skip to main content

Part of Cancer staging guidance sheets

Testis tumours (ICD10 C62)

Previous Chapter

Prostate tumours

Current Chapter

Current chapter – Testis tumours (ICD10 C62)

View all

Next Chapter

Kidney tumours

Page contents

Introduction

This is the data sheet for TNM 8th edition staging of testis tumours (ICD10 C62).

For more detailed information regarding TNM staging, please see pages 195-198 of the UICC TNM 8 book or visit the Wiley and UICC website.

Stage groupings

Stage Group

T stage

N stage

M stage

Serum markers

Stage 0

pTis

N0

M0

S0

Stage I

pT1–T4

N0

M0

SX

Stage IA

pT1

N0

M0

S0

Stage IB

pT2–T4

N0

M0

S0

Stage IS

Any pT/TX

N0

M0

S1 – S3

Stage II

Any pT/TX

N1 – N3

M0

SX

Stage IIA

Any pT/TX

N1

M0

S0

 

Any pT/TX

N1

M0

S1

Stage IIB

Any pT/TX

N2

M0

S0

 

Any pT/TX

N2

M0

S1

Stage IIC

Any pT/TX

N3

M0

S0

 

Any pT/TX

N3

M0

S1

Stage III

Any pT/TX

Any N

M1a

SX

Stage IIIA

Any pT/TX

Any N

M1a

S0

 

Any pT/TX

Any N

M1a

S1

Stage IIIB

Any pT/TX

N1–N3

M0

S2

 

Any pT/TX

Any N

M1a

S2

Stage IIIC

Any pT/TX

N1–N3

M0

S3

 

Any pT/TX

Any N

M1a

S3

 

Any pT/TX

Any N

M1b

Any S

TNM clinical classification

T - primary tumour

Except for pTis and pT4, where radical orchiectomy is not always necessary for classification purposes, the extent of the primary tumour is classified after radical orchiectomy; see pT. In other circumstances, TX is used if no radical orchiectomy has been performed.

N - regional lymph nodes

N value Description

NX

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastasis

N1

Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension

N2

Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension

N3

Metastasis with a lymph node mass more than 5 cm in greatest dimension

M - distant metastasis

M value Description

M0

No distant metastasis

M1

Distant metastasis

M1a

Non‐regional lymph node(s) or lung metastasis

M1b

Distant metastasis other than non‐regional lymph nodes and lung

TNM pathological classification

pT - primary tumour

The pT categories correspond to the T categories as per above.

pT value Description

pTX

Primary tumour cannot be assessed (see T – Primary Tumour)

pT0

No evidence of primary tumour (e.g., histological scar in testis)

pTis

Intratubular germ cell neoplasia (carcinoma in situ)

pT1

Tumour limited to testis and epididymis without vascular/lymphatic invasion; tumour may invade tunica albuginea but not tunica vaginalis*

pT2

Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis

pT3

Tumour invades spermatic cord with or without vascular/lymphatic invasion

pT4

Tumour invades scrotum with or without vascular/lymphatic invasion

Note: 

* AJCC subdivides T1 by T1a and T1b depending on size no greater than 3 cm or greater than 3 cm in greatest dimension

pN - regional lymph nodes

Histological examination of a selective neck dissection specimen will ordinarily include 10 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 15 or more lymph nodes.

pN value Description

pNX

Regional lymph nodes cannot be assessed

pN0

No regional lymph node metastasis

pN1

Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension

pN2

Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumour

pN3

Metastasis with a lymph node mass more than 5 cm in greatest dimension

 

Definition of serum markers

S category

S criteria

SX

Serum marker studies not available or not performed

S0

Serum marker study levels within normal limits

 

S category

LDH

hCG (mIU/ml)

AFP (ng/ml)

S1

<1.5 x N

and <5000

and <1000

S2

1.5 - 10 x N

or 5000 - 50 000

or 1000 - 10 000

S3

>10 x N

or >50 000

or >10 000

Note:

N indicates the upper limit of normal for the LDH assay

Download

Click on the box below to download a PDF version of this data sheet:

Last edited: 29 December 2022 2:01 pm

Previous Chapter

Prostate tumours

Next Chapter

Kidney tumours
  1. Cancer staging guidance sheets
  2. Lip and oral cavity (ICD10 C00, C02-C06)
  3. Malignant melanoma of upper aerodigestive tract (ICD10 C00-06, C10-14, C30-32)
  4. Pharynx (ICD10 C01, C05.1-2, C09, C10.0, C10.2-3, C11-13)
  5. Major salivary glands (ICD10 C07, C08)
  6. Oesophagus including oesophagastric junction (ICD10 C15 & C16.0)
  7. Stomach (ICD10 C16 except C16.0)
  8. Small intestine (ICD10 C17)
  9. Appendix (ICD10 C18.1)
  10. Colon and rectum (ICD10 C18-C20)
  11. Anal canal and perianal skin data (ICD10 C21, C44.5)
  12. Liver (ICD10 C22.0)
  13. Intrahepatic bile ducts (ICD10 C22.1)
  14. Gallbladder (ICD10 C23, C24.0)
  15. Distal extrahepatic bile duct (ICD10 C24.0)
  16. Perihilar bile ducts (ICD10 C24.0)
  17. Ampulla of vater (ICD10 C24.1)
  18. Pancreas (ICD10 C25)
  19. Nasal cavity and paranasal sinuses (ICD10 C30.0, C31.0, C31.1)
  20. Larynx (ICD10 C32.0 C32.1, C32.2, C10.1)
  21. Lung (ICD10 C34)
  22. Thymic tumours (ICD10 C37)
  23. Soft tissues (ICD10 C38.1-2, C47-C49)
  24. Bone (ICD10 C40 & C41)
  25. Malignant melanoma of skin (ICD10 C43, C51.0, C60.9, C63.2)
  26. Merkel cell carcinoma of skin (ICD10 C44 & C63.2)
  27. Skin carcinoma of the head and neck (ICD10 C44.0, C44.2-4)
  28. Carcinoma of skin of the eyelid (ICD10 C44.1)
  29. Carcinoma of skin (excluding eyelid, head and neck, perianal, vulva and penis) (ICD10 C44.5-7, C63.2)
  30. Pleural mesothelioma (ICD10 C45)
  31. Breast tumours (ICD10 C50)
  32. Vulva (ICD10 C51)
  33. Cervix uteri (ICD10 C53)
  34. Uterine sarcomas
  35. Uterus - endometrium (ICD10 C54.1, C55)
  36. Ovarian, fallopian tube and primary peritoneal carcinoma (ICD10 C56, C57, C48.1, C48.2)
  37. Gestational trophoblastic neoplasms (ICD10 C58)
  38. Penis tumours (ICD10 C60)
  39. Prostate tumours (ICD10 C61)
  40. Testis tumours (ICD10 C62)
  41. Kidney tumours (ICD10 C64)
  42. Renal pelvis and ureter tumours (ICD10 C65 & C66)
  43. Urinary bladder tumours (ICD10 C67)
  44. Urethra tumours (ICD10 C68.0)
  45. Carcinoma of conjuctiva (ICD10 C69.0)
  46. Malignant melanoma of conjuctiva (ICD10 C69.0)
  47. Retinoblastoma (ICD10 C69.2)
  48. Malignant melanoma of uvea (ICD10 C69.3, C69.4)
  49. Carcinoma of lacrimal gland (ICD10 C69.5)
  50. Sarcoma of orbit (ICD10 C69.6)
  51. Thyroid gland (ICD10 C73)
  52. Adrenal cortex (ICD10 C74.0)
  53. Chronic lymphocytic leukaemia
  54. Hepatoblastoma (CTYA)
  55. Hodgkins and non-hodgkins lymphoma (ICD10 C81-88)
  56. Medulloblastoma
  57. Multiple myeloma
  58. Neuroblastoma
  59. Neuroendocrine tumours of the foregut
  60. Neuroendocrine tumours of the midgut and hindgut
  61. Non-hodgkin lymphoma (children)
  62. Rhabdomyosarcoma and other soft tissue sarcomas (CTYA)
  63. Wilms tumour of the kidney